<DOC>
	<DOCNO>NCT00830882</DOCNO>
	<brief_summary>The objective study compare peak dose relative bronchoprotection offer levosalbutamol racemic salbutamol mild moderate asthmatic preselected two group basis beta-2 adrenoreceptor polymorphism .</brief_summary>
	<brief_title>Peak Bronchoprotection Conferred Levosalbutamol Racemic Salbutamol</brief_title>
	<detailed_description />
	<mesh_term>Albuterol</mesh_term>
	<criteria>1 . Mild moderate stable asthmatic ≤ 2000μg BDP equivalent 2 . Methacholine responsive PC20 &lt; 4 mg/ml 3 . &gt; 1dd change methacholine PC20 administration racemic Salbutamol . 4 . Male female 1865 5 . Informed Consent 6 . Ability comply requirement protocol 1 . Severe asthmatic define FEV1≤ 60 % PEF variability &gt; 30 % continual daytime nocturnal symptom . 2 . The use oral corticosteroid within last 3 month . 3 . Recent respiratory tract infection ( 2 month ) . 4 . Significant concomitant respiratory disease COPD , CF , ABPA , bronchiectasis active pulmonary tuberculosis . 5 . Any clinically significant medical condition unstable angina , acute myocardial infarction precede 3 month , recent TIA/ CVA , may endanger health safety participant , jeopardise protocol . 6 . Any significant abnormal laboratory result deem investigator 7 . Pregnancy , plan pregnancy lactation 8 . Known suspected contraindication IMP 's 9 . Concomitant use medicine ( prescribe , counter herbal ) may interfere trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>asthma</keyword>
	<keyword>levosalbutamol</keyword>
	<keyword>genotype</keyword>
	<keyword>bronchoprotection</keyword>
</DOC>